Tumor dormancy and MYC inactivation: Pushing cancer to the brink of normalcy

被引:83
作者
Shachaf, CM
Felsher, DW
机构
[1] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Oncol, Div Oncol, Stanford, CA 94305 USA
关键词
D O I
10.1158/0008-5472.CAN-05-1172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Upon MYC inactivation, tumors undergo proliferative arrest, cellular differentiation, apoptosis and in some cases, permanently revoke tumorigenesis. In liver tumor cells, we recently showed that MYC inactivation uncovers stem cell properties and triggers differentiation, but in this case, their neoplastic properties are restorable by MYC reactivation. Thus, whereas oncogene inactivation can push cancer to the brink of normalcy, some cells retain the latent capacity to turn cancerous again, arguing that they may exist in a state of tumor dormancy.
引用
收藏
页码:4471 / 4474
页数:4
相关论文
共 27 条
[1]   Advances in follicular lymphoma [J].
Archuleta, TD ;
Armitage, JO .
SEMINARS IN ONCOLOGY, 2004, 31 (02) :66-71
[2]   MOLECULAR THEMES IN ONCOGENESIS [J].
BISHOP, JM .
CELL, 1991, 64 (02) :235-248
[3]  
Blelloch RH, 2004, P NATL ACAD SCI USA, V101, P13985, DOI 10.1073/pnas.0405015101
[4]   Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation [J].
Boxer, RB ;
Jang, JW ;
Sintasath, L ;
Chodosh, LA .
CANCER CELL, 2004, 6 (06) :577-586
[5]   Essential role for oncogenic Ras in tumour maintenance [J].
Chin, L ;
Tam, A ;
Pomerantz, J ;
Wong, M ;
Holash, J ;
Bardeesy, N ;
Shen, Q ;
O'Hagan, R ;
Pantginis, J ;
Zhou, H ;
Horner, JW ;
Cordon-Cardo, C ;
Yancopoulos, GD ;
DePinho, RA .
NATURE, 1999, 400 (6743) :468-472
[6]   Analysis of a "phase transition" from tumor growth to latency [J].
Delsanto, PP ;
Romano, A ;
Scalerandi, M ;
Pescarmona, GP .
PHYSICAL REVIEW E, 2000, 62 (02) :2547-2554
[7]   Tumour dormancy: findings and hypotheses from clinical research on breast cancer [J].
Demicheli, R .
SEMINARS IN CANCER BIOLOGY, 2001, 11 (04) :297-305
[8]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[9]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[10]   Cancer revoked: oncogenes as therapeutic targets [J].
Felsher, DW .
NATURE REVIEWS CANCER, 2003, 3 (05) :375-380